Tag

Multi District Litigation Archives - Carey Danis & Lowe

Carey Danis & Lowe Issues an Update on the Pradaxa Multi-District Litigation No. 2385

By | Pharmaceutical litigation, Pradaxa, Uncategorized

Published December 27, 2012 by PR Web

St. Louis, MO (PRWEB) December 27, 2012

Carey Danis & Lowe Issues an Update on the Pradaxa Multi-District Litigation No. 2385Pradaxa lawsuits have been consolidated into a Multi-District Litigation being heard in the U.S. District Court, Southern District of Illinois. The Pradaxa MDL has been named Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation. The last Pradaxa MDL meeting occurred on Thursday, December 13, 2012, where Plaintiffs’ representatives as well as the Defendants’ legal counsel convened for a Status Conference.

The MDL No. 2385 is presided over by Chief Judge David R. Herndon in East St. Louis, Illinois. The MDL is currently in the pre-trial discovery phase.

As outlined in the court’s minutes, both sides have been working to approve the First and Second Sets of Discovery gathered by the Plaintiffs legal representatives. Though the two side came to a written agreement on the Second Set of Discovery, in regards to the First, the Plaintiffs’ legal representatives have been working “to resolve pending disputes.”

According to the Pradaxa MDL 2835 Status Conference minutes from December 13, the Plaintiffs’ First Set of Discovery has resulted in a number of unsettled disagreements between the Plaintiffs Lead Counsel and Boehringer Ingelheim Pharmaceuticals, Inc. As court documents detail, Boehringer Ingelheim has objections with regard to the Plaintiffs Lead Counsel’s First Set of Discovery.

As a result of the yet unresolved issues with the First Set of Discovery, Boehringer Ingelheim is filing a protective order, and plans to do so by December 21, 2012. In response to the protective order and in an effort to acquire vital evidence and documents, the Plaintiffs Lead Counsel plans to file a responsive pleading early next year.

Currently, over 170 plaintiffs have a case that has been consolidated into MDL No. 2385. These plaintiffs claim that the ingestion of Pradaxa led to serious Pradaxa-related injuries including excessive bleeding, uncontrollable bleeding, and fatal bleed-outs. Furthermore, these Pradaxa lawsuits claim that Boehringer Ingelheim neglected to warn healthcare providers and patients about the risks of using Pradaxa.

In addition, plaintiffs accuse Boehringer Ingelheim of further negligence in light of Pradaxa’s release onto the market without the simultaneous release of a reversal agent which is vital in treating excessive bleeding. Unlike warfarin which is counteracted by Vitamin K in excessive bleeding episodes, Pradaxa has no known panacea or reversal agent to control excessive bleeding.

Attorneys at Carey Danis & Lowe are currently seeking claims from individuals who have experienced a Pradaxa injury, including those listed above, such as excessive and uncontrollable bleeding events. For more information about filing a Pradaxa lawsuit, contact a defective drug lawyer at Carey Danis & Lowe at 800-721-2519.

Carey Danis & Lowe Evaluating Zoloft Cases and Offers an Update on Zoloft Lawsuits in Zoloft MDL No. 2342

By | Pharmaceutical litigation, Uncategorized, Zoloft

Published January 14, 2013 by PR Web

St. Louis, Missouri (PRWEB) January 14, 2013

Zoloft MDL Updates: Zoloft MDL No. 2342 Progresses with Order to Submit Initial Discovery Zoloft Birth Defect CasesZoloft lawsuits have been consolidated into a Multi-District Litigation in the U.S. District Court for the Eastern District of Pennsylvania. Judge Cynthia M. Rufe is presiding over the Zoloft MDL.

As to recent developments in the Zoloft MDL, on January 2, 2013, Judge Rufe sent forth Pretrial Order No. 16. Fundamentally, the Pretrial Order outlines how to deliver responses in the MDL. The court document imparts detailed information as to “the procedure for filing responses to all civil actions that are or become consolidated in MDL No. 2342”.*

The Pretrial Order goes on to supply information on how the defendants, Pfizer Inc., Greenstone LLC, and Pfizer International LLC, shall go about filing a Master Short-Form Answer. In essence, the Master-Short Form Answer and Affirmative Defense is the defendants’ response to the claims of the plaintiffs.

According to the Pretrial Order, the Defendants will only have the opportunity to file one Master Short-Form Answer, and in doing so can address any and all charges made against them in each of the cases consolidated in the Zoloft MDL. As the document will stand as their initial response to allegations, Pfizer and Greenstone can deny the plaintiffs’ allegations, and in so doing, they can lay out a defense.

If relying upon information supplied in a recent report, there are quite a number of Zoloft cases in the MDL, and therefore each of these cases will necessitate address in the defense’s response. A Florida attorney who sits on the Plaintiffs’ Steering Committee (PSC), Bryan F. Aylstock, recently submitted a report late last year regarding the status of the Zoloft MDL. The legal journal, The Madison-St. Clair Record, stated that according to information contained in Alystock’s report, there are over 250 cases that have been consolidated into the Zoloft MDL.*

Plaintiffs in the Zoloft MDL have filed lawsuits against Pfizer, the manufacturer of Zoloft, claiming that the antidepressant drug, classified as a selective serotonin re-uptake inhibitor (SSRI), causes birth defects in newborn children when taken by women during pregnancy.

In a separate Zoloft lawsuit being heard in the Wayne County Circuit Court in West Virginia, nineteen plaintiffs, who are the children of mothers who claimed to have taken Zoloft during pregnancy, filed their lawsuit alleging that exposure to Zoloft in the womb resulted in the development of their birth defects.

According to the legal journal, The West Virginia Record, the plaintiffs identified these Zoloft linked birth defects as heart defects, such as atrial septal defects and holes in the heart, persistent pulmonary hypertension of the newborn (PPHN), skull and facial deformations, and a number of other congenital birth defects related to Zoloft exposure in utero.*

Lawyers at Carey Danis & Lowe are currently evaluating Zoloft cases, and they are offering legal consultations to those individuals who claim to have been harmed by the use of Zoloft during pregnancy. For more information about filing a Zoloft lawsuit, and specifically one related to Zoloft and birth defects, contact a lawyer at Carey Danis & Lowe by calling 800-721-2519.

Minnesota Levaquin MDL and New Jersey Levaquin Mass Tort Plaintiffs Claim Serious Tendon Damage

By | Levaquin, Pharmaceutical litigation, Uncategorized

Minnesota Levaquin MDL and New Jersey Levaquin Mass Tort Plaintiffs Claim Serious Tendon DamageLevaquin, a drug manufactured by a Johnson & Johnson subsidiary – OrthoMcNeil Pharmaceutical, Inc. – is the topic of several lawsuits around the country that have since been consolidated into a Multi-District Litigation based in Minnesota. A mass tort litigation has been arranged in a New Jersey court.

Levaquin is a drug used to treat bacterial infections occurring in the lungs, urinary tract, skin, and other areas of the body. It soon became apparent that Levaquin was the cause of serious and painful side effects, primarily targeting patients’ tendons. Plaintiffs in the Minnesota MDL and the New Jersey mass tort litigation claim that Levaquin caused tendonitis, tendon rupture, joint immobility, and other joint complications.

As a result of increasing adverse event reports filed with the U.S. Food and Drug Administration (FDA), OrthoMcNeil was ordered to update Levaquin’s label with information regarding Levaquin tendon damage.

According to court minutes from a Status Conference held in the U.S. District Court for the District of Minnesota on December 4, 2012, the parties involved in the MDL are currently in negotiations relating to a three phase settlement. The goal of the settlement negotiations is to have the terms of the settlement defined early this year.

One case in the Minnesota Levaquin MDL is set to go to trial on March 5, 2013. Prior to that date, as outlined in the Status Conference court minutes, the Defense intends to put a number of motions in limine, and in particular the Defense is aiming to exclude expert testimony provided by a doctor. A ruling has not yet been made about the Defense’s request to put motions in limine.

The next Status Conference for the Minnesota Levaquin MDL is scheduled for January 8, 2013.

As detailed in an updated case document released in mid-December 2012, there are currently 1,835 cases pending in the New Jersey Levaquin mass tort litigation. The most recent case filed with the New Jersey court was done so on December 10, 2012. Bellwether trials in the New Jersey court have been scheduled for June of this year.

If you or a loved one has experienced one or more of the serious side effects linked to the use of Levaquin, such as tendonitis, tendon rupture, or other tendon damage, lawyers at Carey Danis & Lowe can help you and your loved one win the compensation for such an undeserved amount of suffering, pain, and losses.

Our experienced pharmaceutical product liability trial lawyers understand the importance of holding pharmaceutical giants like Johnson & Johnson and OrthoMcNeil Pharmaceutical, Inc. responsible for putting defective drugs onto the market. We work closely with our clients in Levaquin lawsuits to win them the justice they so rightfully deserve.

To file a Levaquin lawsuit, contact a lawyer at Carey Danis & Lowe today by calling 800.721.2519.

First Trials for Defective DePuy ASR Hip Replacement System Set for January 2013

By | Defective Medical Device litigation, Hip/Knee Replacement, Uncategorized

First Trials for Defective DePuy ASR Hip Replacement System Set for January 2013A state case regarding the recalled DePuy ASR hip replacement system is scheduled to go to trial in January 2013 in Prince George’s County, Maryland. If DePuy does not settle with plaintiffs before trials begin, the Maryland court will hear three cases regarding health complications related to DePuy’s ASR hip implants.

In August 2012, DePuy, a subsidiary of Johnson & Johnson, settled state cases in Nevada regarding defective ASR hip replacement lawsuits. Trials for these ASR hip replacement cases filed against DePuy were scheduled to begin in December 2012, but due to the settlement, trial dates have since been canceled. The individuals in each Nevada case received $200,000 each, according to a Bloomberg News report.

In 2010, due to what they claimed to be poor sales as opposed to the escalating reports of ASR hip replacement failures, Johnson & Johnson’s DePuy initiated a worldwide recall of 93,000 ASR hip replacement systems. Ultimately, DePuy admitted that the recall was the result of the high ASR hip replacement failure rate.

Individuals who have filed lawsuits against DePuy have claimed that DePuy’s defective ASR hip replacement system resulted in numerous painful revision surgeries, severe pain, dislocated joints, joint malfunction and dislocation, infection, bone fractures, and metallosis. Plaintiffs claim that the unique design of the ASR hip replacement, being a metal-on-metal total hip replacement, led to an accumulation of metal flakes inside of the body.

6,000 DePuy ASR hip replacement lawsuits have been consolidated into a Multi-District Litigation based in Toledo, Ohio overseen by U.S. District Judge David A. Katz. There are another 2,000 cases filed against Johnson & Johnson’s DePuy in states across the U.S., including those in Nevada, Maryland, California, Wisconsin, Florida, and Utah.

The MDL No. 2197 based in Ohio is due to convene for a Status Conference in January 2013, during which time the court will most likely detail preparations for the first bellwether trials scheduled to begin in May 2013.

To file a DePuy ASR hip replacement lawsuit, contact an experienced defective medical device lawyer at Carey Danis & Lowe.

Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent Litigation

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

Published October 12, 2012 by LawsuitInformation.org

Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent LitigationIn recent news regarding Bayer Pharmaceuticals, the German pharmaceutical giant responsible for the manufacture of Yaz and Yasmin, the Federal Trade Commission made the decision to terminate its investigation into a patent settlement between Bayer and Teva Pharmaceuticals.

In 2008, the two pharmaceutical companies reached an agreement in regards to Bayer’s claim that Barr Laboratories, which was ultimately purchased by Teva Pharmaceuticals, overstepped the boundaries of intellectual property protecting Bayer’s Yasmin patent. The 2008 settlement drew the attention of the FTC, and led to a four year investigation into the settlement agreement’s possible antitrust violations.

Though the investigation has ended, Bayer Pharmaceuticals is still tied up in a Multi-District Litigation in the Southern District of Illinois regarding a large number of Yaz and Yasmin lawsuits.

The U.S. Food and Drug Administration released data last October 2011 regarding a Yaz and Yasmin study they conducted in order to determine the drug’s link to the development of blood clots in women. The FDA’s research indicated that among the approximately 800,000 women, they recorded an increased risk of suffering from the development of a blood clot.

It is believed that the chemical drospirenone, which is present in both Yaz and Yasmin, causes health complications in women. The presence of drospirenone in the body elevates levels of potassium, and thus, puts women at a higher risk of developing a blood clot.

Yaz and Yasmin side effects include:

  • Blood clots
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism

Deep Vein Thrombosis is a serious health condition in which a blood clot forms in a deep vein, most often in a vein in the leg. DVT has been known to cause extreme pain in the location of the blood clot. The danger of DVT is the blood clot migrating to the lungs or brain, causing a more serious and life-threatening condition.

Pulmonary Embolism occurs when a blood clot enters an artery in the lungs, thus obstructing the normal flow of blood to the lungs, and resulting in a lack of oxygen delivery throughout the entire body.

If you or a loved one has suffered from a blood clot caused by the use of either Yaz or Yasmin, you may be eligible to receive compensation for your suffering. To file a Yaz lawsuit or a Yasmin lawsuit, contact our experienced pharmaceutical litigation lawyers at Carey Danis & Lowe.